Evaluation du site pharmaphorum.com
pharmaphorum | News & views on pharma and biotech’s evolving future
Généré le 06 Mars 2026 13:56
Vieilles statistiques? UPDATE !
Le score est de 56/100
Optimisation du contenu
Titre
pharmaphorum | News & views on pharma and biotech’s evolving future
Longueur : 67
Parfait, votre titre contient entre 10 et 70 caractères.
Description
pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future.
Longueur : 158
Génial, votre balise META description contient entre 70 et 160 caractères.
Mots-clefs
Très mauvais. Nous n'avons pas trouvé de balise META keywords sur votre page. Utilisez ce générateur gratuit de balises META en ligne pour créer des mots-clés.
Propriétés Open Graph
Bien, cette page profite des balises META Open Graph.
| Propriété | Contenu |
|---|---|
| site_name | pharmaphorum |
| url | https://pharmaphorum.com/homepage |
| title | pharmaphorum| News & views on pharma and biotech’s evolving future |
| description | Pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future. |
Niveaux de titre
| H1 | H2 | H3 | H4 | H5 | H6 |
| 0 | 7 | 37 | 0 | 12 | 0 |
- [H2] Featured Content
- [H2] Latest News
- [H2] Views & Analysis
- [H2] Deep Dive
- [H2] White Papers & Webinar
- [H2] Podcasts & Video
- [H2] Partner Content
- [H3] China's clears Pfizer GLP-1 ecnoglutide for weight loss
- [H3] J&J's Tecvayli claims third national priority FDA approval
- [H3] The GLP-1 Reckoning
- [H3] Alnylam bets on Tenaya RNAi tech, and other licensing news
- [H3] What US healthcare companies and medical researchers need to...
- [H3] What US healthcare companies and medical researchers need to...
- [H3] The GLP-1 Reckoning
- [H3] Using AI-driven synthetic personas to take your insights fur...
- [H3] AI in clinical development & ‘white space’, with Andrew Mack...
- [H3] New hope for ovarian cancer, with Alexander Schneider
- [H3] Expert Directed Applied Intelligence: Redefining AI in Life ...
- [H3] Editor's Picks
- [H3] China's clears Pfizer GLP-1 ecnoglutide for weight loss
- [H3] J&J's Tecvayli claims third national priority FDA approval
- [H3] Alnylam bets on Tenaya RNAi tech, and other licensing news
- [H3] Lilly unveils employer scheme for weight-loss drug Zepbound
- [H3] What US healthcare companies and medical researchers need to...
- [H3] JPM 2026: What it revealed about biotech’s new reality
- [H3] Pharma’s search loophole is a preview of what comes next
- [H3] Legacy data into living scientific memory
- [H3] The GLP-1 Reckoning
- [H3] GLP-1s: Five years that changed metabolic medicine
- [H3] Redesigning obesity trials for a chronic disease era
- [H3] The trust gap: GLP-1s and the new information economy of obe...
- [H3] Using AI-driven synthetic personas to take your insights fur...
- [H3] Expert Directed Applied Intelligence: Redefining AI in Life ...
- [H3] The strategic imperative of Integrated Evidence Generation P...
- [H3] Data managers and CRAs warn of rising data quality risks due...
- [H3] AI in clinical development & ‘white space’, with Andrew Mack...
- [H3] Collaboration & personalisation in rare disease R&D, with AO...
- [H3] Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...
- [H3] On JPM2026 and healthcare investment today, with Jonah Comst...
- [H3] 7th Dermatology Drug Development Summit Europe
- [H3] The PM Society Launches Pharmony to Support More Effective P...
- [H3] EVERSANA Names Monica Avram Executive Vice President and Chi...
- [H3] Emerging Trends in Personalised Medicine at PHARMAP 2026
- [H3] Book your tickets and join the PM Society for the 40th PM Aw...
- [H5] header links
- [H5] Pharmaphorum menu first category
- [H5] SECTION
- [H5] Channels
- [H5] Channels
- [H5] SUB NAVIGATION
- [H5] US lawmakers take FDA to task over rare diseases record
- [H5] Gilead buys cell therapy partner Arcellx for up to $7.8bn
- [H5] What next for pharma as SCOTUS strikes down Trump tariffs?
- [H5] Novo Nordisk to cut GLP-1 prices in tough US market
- [H5] UK spurs prescribing of obesity jab Mounjaro with GP bonus
- [H5] Pharmaphorum Menu
Images
Nous avons trouvé 42 image(s) sur cette page Web.
Bien, la plupart ou la totalité de vos images possèdent un attribut alt
Ratio texte/HTML
Ratio : 18%
Bien, le ratio de cette page texte/HTML est supérieur à 15, mais inférieur à 25 pour cent.
Flash
Parfait, aucun contenu FLASH n'a été détecté sur cette page.
Iframe
Dommage, vous avez des Iframes sur vos pages Web, cela signifie que son contenu ne peut pas être indexé par les moteurs de recherche.
Liens
Réécriture d'URLs
Bien. Vos liens sont optimisés!
Tiret bas dans les URLs
Nous avons détectés des soulignements dans vos URLs. Vous devriez plutôt utiliser des tirets pour optimiser votre référencement.
Liens dans la page
Nous avons trouvé un total de 136 lien(s) dont 1 lien(s) vers des fichiers
| Texte d'ancre | Type | Juice |
|---|---|---|
| Skip to main content | Interne | Passing Juice |
| BlueSky | Externe | Passing Juice |
| Externe | Passing Juice | |
| youtube | Externe | Passing Juice |
| Get Newsletters | Interne | Passing Juice |
| Media Kit | Interne | Passing Juice |
| News | Interne | Passing Juice |
| Views & Analysis | Interne | Passing Juice |
| Deep Dive | Interne | Passing Juice |
| Equity and Sustainability | Interne | Passing Juice |
| Research & Development | Interne | Passing Juice |
| Market Access | Interne | Passing Juice |
| Oncology | Interne | Passing Juice |
| Artificial Intelligence | Interne | Passing Juice |
| Patients & Partnerships | Interne | Passing Juice |
| GLP-1 | Interne | Passing Juice |
| Previous Editions | Interne | Passing Juice |
| Webinars | Interne | Passing Juice |
| Podcasts | Interne | Passing Juice |
| Videos | Interne | Passing Juice |
| Spotlight on | Interne | Passing Juice |
| ASCO 2025 | Interne | Passing Juice |
| BIO 2025 | Interne | Passing Juice |
| C-Suite Innovators | Interne | Passing Juice |
| ESMO 2025 | Interne | Passing Juice |
| Frontiers Health 2025 | Interne | Passing Juice |
| JP Morgan | Interne | Passing Juice |
| Global Policy Insights | Interne | Passing Juice |
| Events | Interne | Passing Juice |
| close | Externe | Passing Juice |
| Market Access | Interne | Passing Juice |
| Oncology | Interne | Passing Juice |
| Patients & Partnerships | Interne | Passing Juice |
| Commercialisation | Interne | Passing Juice |
| White Papers | Interne | Passing Juice |
| Sales & Marketing | Interne | Passing Juice |
| R&D | Interne | Passing Juice |
| Digital | Interne | Passing Juice |
| Market Access | Interne | Passing Juice |
| Oncology | Interne | Passing Juice |
| Patients | Interne | Passing Juice |
| Live Coverage | Interne | Passing Juice |
| Partner Content | Interne | Passing Juice |
| About us | Interne | Passing Juice |
| Contribute | Interne | Passing Juice |
| Contact us | Interne | Passing Juice |
| Sign in | Interne | Passing Juice |
| China's clears Pfizer GLP-1 ecnoglutide for weight loss | Interne | Passing Juice |
| J&J's Tecvayli claims third national priority FDA approval | Interne | Passing Juice |
| The GLP-1 Reckoning | Interne | Passing Juice |
| Alnylam bets on Tenaya RNAi tech, and other licensing news | Interne | Passing Juice |
| What US healthcare companies and medical researchers need to... | Interne | Passing Juice |
| Using AI-driven synthetic personas to take your insights fur... | Interne | Passing Juice |
| AI in clinical development & ‘white space’, with Andrew Mack... | Interne | Passing Juice |
| New hope for ovarian cancer, with Alexander Schneider | Interne | Passing Juice |
| Expert Directed Applied Intelligence: Redefining AI in Life ... | Interne | Passing Juice |
| US lawmakers take FDA to task over rare diseases record | Interne | Passing Juice |
| Gilead buys cell therapy partner Arcellx for up to $7.8bn | Interne | Passing Juice |
| What next for pharma as SCOTUS strikes down Trump tariffs? | Interne | Passing Juice |
| Novo Nordisk to cut GLP-1 prices in tough US market | Interne | Passing Juice |
| UK spurs prescribing of obesity jab Mounjaro with GP bonus | Interne | Passing Juice |
| Subscribe | Interne | Passing Juice |
| Lilly unveils employer scheme for weight-loss drug Zepbound | Interne | Passing Juice |
| JPM 2026: What it revealed about biotech’s new reality | Interne | Passing Juice |
| Pharma’s search loophole is a preview of what comes next | Interne | Passing Juice |
| Legacy data into living scientific memory | Interne | Passing Juice |
| GLP-1s: Five years that changed metabolic medicine | Interne | Passing Juice |
| Redesigning obesity trials for a chronic disease era | Interne | Passing Juice |
| The trust gap: GLP-1s and the new information economy of obe... | Interne | Passing Juice |
| The strategic imperative of Integrated Evidence Generation P... | Interne | Passing Juice |
| Data managers and CRAs warn of rising data quality risks due... | Interne | Passing Juice |
| Collaboration & personalisation in rare disease R&D, with AO... | Interne | Passing Juice |
| Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al... | Interne | Passing Juice |
| On JPM2026 and healthcare investment today, with Jonah Comst... | Interne | Passing Juice |
| 7th Dermatology Drug Development Summit Europe | Interne | Passing Juice |
| The PM Society Launches Pharmony to Support More Effective P... | Interne | Passing Juice |
| EVERSANA Names Monica Avram Executive Vice President and Chi... | Interne | Passing Juice |
| Emerging Trends in Personalised Medicine at PHARMAP 2026 | Interne | Passing Juice |
| Book your tickets and join the PM Society for the 40th PM Aw... | Interne | Passing Juice |
| News | Interne | Passing Juice |
| Views & Analysis | Interne | Passing Juice |
| Deep Dive | Interne | Passing Juice |
| Webinars | Interne | Passing Juice |
| Podcasts | Interne | Passing Juice |
| Video | Interne | Passing Juice |
| White Papers | Interne | Passing Juice |
| Event | Interne | Passing Juice |
| News | Interne | Passing Juice |
| Views & Analysis | Interne | Passing Juice |
| Deep Dive | Interne | Passing Juice |
| Webinars | Interne | Passing Juice |
| Podcasts | Interne | Passing Juice |
| Video | Interne | Passing Juice |
| White Papers | Interne | Passing Juice |
| Event | Interne | Passing Juice |
| News | Interne | Passing Juice |
| Views & Analysis | Interne | Passing Juice |
| Deep Dive | Interne | Passing Juice |
| Webinars | Interne | Passing Juice |
| Podcasts | Interne | Passing Juice |
| Video | Interne | Passing Juice |
| White Papers | Interne | Passing Juice |
| Event | Interne | Passing Juice |
| News | Interne | Passing Juice |
| Views & Analysis | Interne | Passing Juice |
| Deep Dive | Interne | Passing Juice |
| Webinars | Interne | Passing Juice |
| Podcasts | Interne | Passing Juice |
| Video | Interne | Passing Juice |
| White Papers | Interne | Passing Juice |
| Event | Interne | Passing Juice |
| News | Interne | Passing Juice |
| Views & Analysis | Interne | Passing Juice |
| Deep Dive | Interne | Passing Juice |
| Webinars | Interne | Passing Juice |
| Podcasts | Interne | Passing Juice |
| Video | Interne | Passing Juice |
| White Papers | Interne | Passing Juice |
| Event | Interne | Passing Juice |
| News | Interne | Passing Juice |
| Views & Analysis | Interne | Passing Juice |
| Deep Dive | Interne | Passing Juice |
| Webinars | Interne | Passing Juice |
| Podcasts | Interne | Passing Juice |
| Video | Interne | Passing Juice |
| White Papers | Interne | Passing Juice |
| Event | Interne | Passing Juice |
| Axtria Ignite 2025 | Interne | Passing Juice |
| Frontiers Health 2024 | Interne | Passing Juice |
| Life Science Industry Report | Interne | Passing Juice |
| World Without Disease Summit | Interne | Passing Juice |
| Pharmaphorum | Interne | Passing Juice |
| Cookie Policy | Interne | Passing Juice |
| Privacy Policy | Interne | Passing Juice |
| Terms & Conditions | Interne | Passing Juice |
| Work for us | Interne | Passing Juice |
Mots-clefs
Nuage de mots-clefs
healthcare news digital sponsored pharmaphorum glp-1 dive content white event
Cohérence des mots-clefs
| Mot-clef | Contenu | Titre | Mots-clefs | Description | Niveaux de titre |
|---|---|---|---|---|---|
| news | 17 |  |
 |
|
|
| white | 11 | |
|
|
|
| event | 10 | |
|
|
|
| healthcare | 9 | |
|
|
|
| content | 9 | |
|
|
|
Ergonomie
Url
Domaine : pharmaphorum.com
Longueur : 16
Favicon
Génial, votre site web dispose d'un favicon.
Imprimabilité
Aucun style CSS pour optimiser l'impression n'a pu être trouvé.
Langue
Bien. Votre langue est : en.
Dublin Core
Cette page ne profite pas des métadonnées Dublin Core.
Document
Doctype
HTML 5
Encodage
Parfait. Votre charset est UTF-8.
Validité W3C
Erreurs : 0
Avertissements : 0
E-mail confidentialité
Génial, aucune adresse e-mail n'a été trouvé sous forme de texte!
HTML obsolètes
Génial! Nous n'avons pas trouvé de balises HTML obsolètes dans votre code.
Astuces vitesse
|
Excellent, votre site n'utilise pas de tableaux imbriqués. |
|
Mauvais, votre site web utilise des styles css inline. |
|
Génial, votre site web contient peu de fichiers CSS. |
|
Mauvais, votre site web contient trop de fichiers javascript (plus de 6). |
|
Parfait : votre site tire parti de gzip. |
Mobile
Optimisation mobile
|
Icône Apple |
|
Méta tags viewport |
|
Contenu FLASH |
Optimisation
Sitemap XML
Votre site web dispose d’une sitemap XML, ce qui est optimal.
| https://pharmaphorum.com/sitemap.xml |
Robots.txt
https://pharmaphorum.com/robots.txt
Votre site dispose d’un fichier robots.txt, ce qui est optimal.
Mesures d'audience
Votre site web dispose d’une outil d'analytics, ce qui est optimal.
Google Analytics |
PageSpeed Insights
Dispositif
Les catégories
Free SEO Testing Tool
Free SEO Testing Tool est un outil gratuit de référencement qui vous aidera à analyser vos pages web